Mallory Kowalski
Family · Newark, DENPI 1356746382
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,107 of the $6,628 with a category attached, or 62.0%. Medtronic accounts for 61.3% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2023 at $2,831 and has fallen 76.5% since, to $665 in 2025. Among family clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 209 payments — averaging $31.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$752
- Collegium Pharmaceutical, Inc.$599
- Scilex Pharmaceuticals Inc.$272
- AbbVie$227
- Biodelivery Sciences International, Inc.$126
- plus $589 from 14 others
What the payments were for
- Travel & lodging$2,41436%
- Food & beverage$4,10762%
- Education$1082%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 36 | $4,064 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 60 | $752 |
| Collegium Pharmaceutical, Inc. | 45 | $599 |
| Scilex Pharmaceuticals Inc. | 14 | $272 |
| AbbVie | 10 | $227 |
| Biodelivery Sciences International, Inc. | 13 | $126 |
| Valinor Pharma, LLC | 5 | $84 |
| Vertex | 4 | $82 |
| Azurity Pharmaceuticals, Inc. | 2 | $78 |
| GRT US Holding, Inc. | 4 | $72 |
| Kowa Pharmaceuticals America, Inc. | 5 | $70 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Pfizer | 2 | $31 |
| Biogen | 1 | $24 |
| Lilly USA, LLC | 1 | $23 |
| Averitas Pharma Inc. | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Almatica Pharma LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNCHROMEDII$2,851
- INTELLIS ADAPTIVESTIM$120
How this compares
$6,628 in reported general payments places this provider in the 90th percentile of 523 family providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 126 | $120,436 |
| OxycontinOxycodone Hcl | 97 | $58,905 |
| RelistorMethylnaltrexone Bromide | 18 | $45,949 |
| Xtampza ErOxycodone Myristate | 86 | $45,678 |
| MounjaroTirzepatide | 30 | $31,529 |
| OzempicSemaglutide | 17 | $26,357 |
| Buprenorphine | 102 | $24,763 |
| NucyntaTapentadol Hcl | 13 | $18,983 |
| Nurtec OdtRimegepant Sulfate | 18 | $17,835 |
| Oxycodone Hcl | 804 | $14,692 |
| Emgality PenGalcanezumab-Gnlm | 18 | $12,662 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 458 | $12,307 |
| Morphine Sulfate ErMorphine Sulfate | 298 | $9,813 |
| Lidocaine | 52 | $9,453 |
| Gabapentin | 388 | $7,897 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta | $599 | $185,097225 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $752 | $45,94918 claims |
| Lilly USA, LLCMounjaro | $23 | $31,52930 claims |
| Novo NordiskOzempic | $16 | $26,35717 claims |
| PfizerNurtec Odt | $31 | $17,83518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 523 family providers in Delaware.
Other family in Newark
- Kathy GallagherNewark$53K
- Jodie DelesioNewark$50K
- Melanie HiesterNewark$9K
- Samatha GrayNewark$9K
- Byron MayNewark$8K
- Clare MatisNewark$8K
- Christine MazzolaNewark$7K
- Kelsey FrybergerNewark$7K
- Colleen AllenNewark$7K
- Palak DesaiNewark$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.